Impact of pre-emptive rapid testing for glucose-6-phosphate dehydrogenase deficiency prior to rasburicase administration at a tertiary care centre: A retrospective study.

Ganapathi, Mythily; Campbell, Peter; Ofori, Kenneth; Aggarwal, Vimla; Francis, Richard O; Kratz, Alexander

Ganapathi, Mythily; Campbell, Peter; Ofori, Kenneth; Aggarwal, Vimla; Francis, Richard O; Kratz, Alexander.

Afiliação

Ganapathi M; Department of Pathology & Cell Biology, Columbia University Irving Medical Center, New York, NY, USA.
Campbell P; Department of Pharmacy, NewYork-Presbyterian Hospital, Columbia University Irving Medical Center, New York, NY, USA.
Ofori K; Department of Pathology & Cell Biology, Columbia University Irving Medical Center, New York, NY, USA.
Aggarwal V; Department of Pathology & Cell Biology, Columbia University Irving Medical Center, New York, NY, USA.
Francis RO; Department of Pathology & Cell Biology, Columbia University Irving Medical Center, New York, NY, USA.
Kratz A; Department of Pathology & Cell Biology, Columbia University Irving Medical Center, New York, NY, USA.

Br J Clin Pharmacol ; 88(9): 4163-4170, 2022 09.

Article em En | MEDLINE | ID: mdl-35419830

Assuntos

Deficiência de Glucosefosfato Desidrogenase; Urato Oxidase; Feminino; Deficiência de Glucosefosfato Desidrogenase/complicações; Deficiência de Glucosefosfato Desidrogenase/diagnóstico; Hemólise; Humanos; Estudos Retrospectivos; Centros de Atenção Terciária; Urato Oxidase/administração & dosagem; Urato Oxidase/efeitos adversos; Ácido Úrico

Palavras-chave

adverse reaction; glucose-6-phosphate dehydrogenase; haemolysis; methemoglobinaemia; pharmacogenomics; rapid testing; rasburicase; tumour lysis syndrome; uric acid

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Urato Oxidase / Deficiência de Glucosefosfato Desidrogenase Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google